tbuckley/cabot-search huggingface dataset:
Study on external Chinese herbal medicine LC07 treating capecitabine-induced hand-foot syndrome in metastatic breast cancer
Authors: L. Jia, Y. Lou, H. Tan
Journal: Journal of Clinical Oncology (2009)

1088 Background: With the capecitabine being increasingly used in the treatment of metastatic breast cancer (MBC), the common side effect of capecitabine, hand-foot syndrome (HFS) has become a main problem which can distress both physicians and patients. Severe HFS such as severe pain can have a negative impact on quality of life (QOL) of these patients and cause reduced dosage or even stopping chemotherapy. No effective treatment for HFS can be available at present. Over the years we have used LC07, a kind of external agents from Chinese herbs (Herba Geranii, etc.), to treat capecitabine-induced HFS. In this study, the efficacy and safety of LC07 were evaluated in patients with MBC and HSF. Methods: Eligible patients includes patients with MBC, who had HFS (NCI-CTC grade ≥1) after receiving single capecitabine chemotherapy (1,250 mg/m 2 , PO, twice daily, cycled days 1–14, every 21 days). LC07 granules 10g was dissolved in 1,000mL of warm water (keep 34°C-37°C in a footbath), the patients soaked their feet and hands in this lotion for 20 minutes, twice daily for 7 days. An independent researcher assessed symptoms before and after treatment. Evaluation criteria, CR as symptom disappearing completely, PR as NCI-CTC grade for HFS decreasing by more than 1 level after treatment, the total response rate as CR+PR. The QOL of these patients were also evaluated before and after treatment using a FACT-B questionnaire (Version 4.0-Chinese). Results: 42 patients (pts) have been enrolled in this study. All of them are Asian and female. Media age 51.5 yrs (25–72). Grade 1 for HFS was seen in 8 pts, G2 in 19 pts, and G3 in 15 pts. The total response rate was 83.3% (35/42), CR 38.1% (16/42), PR 45.2% (19/42). The average time from therapy to pain relief was 1.8±0.8 days, the skin lesion of HFS including dermatitis, peeling, ulceration have been improved after treatment. The QOL scores before and after treatment were 77.24±25.69 and 109.17±20.53, respectively (p &lt; 0.01). No side effects such as skin allergies related to LC07 was found in this study. Conclusions: In the treatment of capecitabine-induced HFS, the external Chinese medicine LC07 is fast effective for relieving pain, and it has the features of easy use and no skin allergies. Thus LC07 can improve the QOL of patients with MBC and HFS. No significant financial relationships to disclose.
Cytokine Profiles in Breast Milk in Relation with Atopic Manifestations of Mothers and Infants: Study in Asian Population.
Authors: Sirapassorn Sornphiphatphong, Pantipa Chatchatee, Jarungchit Ngamphaiboon, Sirinuch Chomtho, Nattiya Hirankarn, Narissara Suratannon
Journal: Journal of Allergy and Clinical Immunology (2016)
The Consult Guys - Homans Sign: A Sign of What?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2016)

Web Exclusives15 March 2016The Consult Guys - Homans Sign: A Sign of What?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W16-0003 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Consult Guys bring a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on The Consult Guys, visit www.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Yehia Y. Mishriki, MD, FACPLehigh Valley Health Network19 May 2016 Homans' sign, not the only "sign" in DVT The inframalleolar bruise is otherwise known as the "crescent sign".Interestingly, many other signs have been described in patients with suspected DVT of the lower extremity but have never been formally tested for their sensitivity and/or specificity. These include Moses' or Bancroft's sign, Lisker's sign, Pratt's sign, Lowenberg's sign, Louvel's sign and Ramirez sign. There is also Peabody's technique in suspected gastrocnemius/soleus spasm causing calf pain. Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCorrection: The Consult Guys - A Real Headache: Anticoagulation and a Subdural Hematoma 15 March 2016Volume 164, Issue 6Page: CG1KeywordsDisclosureResearch grantsResearch reporting guidelines ePublished: 15 March 2016 Issue Published: 15 March 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
Dangerous behavior by Viet Nam veterans with schizophrenia
Authors: J A Yesavage
Journal: American Journal of Psychiatry (1983)

The military histories of 80 Viet Nam era veterans diagnosed as schizophrenic by DSM-III criteria were examined in relation to measures of dangerous and violent acts. Thirty of the subjects had been in Viet Nam, and 20 of these had been in combat. A stepwise multiple regression analysis indicated that high scores on several inpatient and outpatient measures of violence and dangerousness were significantly related to combat experience in Viet Nam and particularly to either killing or witnessing killings of the enemy. It appears that violence-related activities learned in Viet Nam continue to influence the behavior of schizophrenic patients.
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group
Authors: Kieuhoa T. Vo, Jeremy V. Edwards, C. Lorrie Epling, Elizabeth Sinclair, Douglas S. Hawkins, Holcombe E. Grier, Katherine A. Janeway, Phillip Barnette, Elizabeth McIlvaine, Mark D. Krailo, Donald A. Barkauskas, Katherine K. Matthay, Richard B. Womer, Richard G. Gorlick, Stephen L. Lessnick, Crystal L. Mackall, Steven G. DuBois
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Flow cytometry and RT-PCR can detect occult Ewing sarcoma cells in the blood and bone marrow. These techniques were used to evaluate the prognostic significance of micrometastatic disease in Ewing sarcoma. Experimental Design: Newly diagnosed patients with Ewing sarcoma were enrolled on two prospective multicenter studies. In the flow cytometry cohort, patients were defined as “positive” for bone marrow micrometastatic disease if their CD99+/CD45− values were above the upper limit in 22 control patients. In the PCR cohort, RT-PCR on blood or bone marrow samples classified the patients as “positive” or “negative” for EWSR1/FLI1 translocations. The association between micrometastatic disease burden with clinical features and outcome was assessed. Coexpression of insulin-like growth factor-1 receptor (IGF-1R) on detected tumor cells was performed in a subset of flow cytometry samples. Results: The median total bone marrow CD99+CD45− percent was 0.0012% (range 0%–1.10%) in the flow cytometry cohort, with 14 of 109 (12.8%) of Ewing sarcoma patients defined as “positive.” In the PCR cohort, 19.6% (44/225) patients were “positive” for any EWSR1/FLI1 translocation in blood or bone marrow. There were no differences in baseline clinical features or event-free or overall survival between patients classified as “positive” versus “negative” by either method. CD99+CD45− cells had significantly higher IGF-1R expression compared with CD45+ hematopoietic cells (mean geometric mean fluorescence intensity 982.7 vs. 190.9; P &amp;lt; 0.001). Conclusions: The detection of micrometastatic disease at initial diagnosis by flow cytometry or RT-PCR is not associated with outcome in newly diagnosed patients with Ewing sarcoma. Flow cytometry provides a tool to characterize occult micrometastatic tumor cells for proteins of interest. Clin Cancer Res; 22(14); 3643–50. ©2016 AACR.
Power of study was not estimated
Authors: H. Rampes
Journal: BMJ (1995)

<b>Objective:</b> To study the effects of closure of interatrial communications associated with a right to left shunt in patients with congenital heart disease (CHD) who had a biventricular repair. <b>Design:</b> Retrospective study. <b>Setting:</b> Tertiary referral centre. <b>Patients:</b> 15 patients with CHD with right to left shunt through an interatrial communication: three had repaired tetralogy of Fallot, five had repaired pulmonary atresia with intact ventricular septum, four had Ebstein’s disease, and three had other CHDs. Two patients had had a stroke before closure of the interatrial communication. <b>Interventions:</b> Percutaneous atrial septal defect (n = 6) or persistent foramen ovale (n = 9) closure. All patients underwent an exercise test before and after interatrial communication closure. <b>Results:</b> Five patients were cyanotic at rest. During exercise, mean (SD) oxygen saturation diminished from 93.9 (3.8)% to 84.3 (4.8)% (p &lt; 0.05). Interatrial communication closure led to an immediate increase of oxygen saturation from 93.9 (3.8)% to 98.6 (1.6)% (p &lt; 0.05). At a median follow up of three years (range 0.5–5) all but one patient with a residual atrial septal defect had normal oxygen saturation at rest and during exercise. Maximum workload increased from 7.2 (1.9) to 9.0 (2.2) metabolic equivalents (p &lt; 0.001). <b>Conclusions:</b> Percutaneous closure of interatrial communications associated with a right to left shunt allows restoration of normal oxygen saturation at rest, avoidance of desaturation during exercise, and improvement of exercise performance in patients with CHD.
RARE-08SPINDLE CELL ONCOCYTOMA OF THE PITUITARY GLAND: CASE REPORT AND LITERATURE REVIEW
Authors: Mansour Mathkour, Juanita Garces, Tyler Scullen, Edison Valle, Shams Halat, Teresa Arrington, Marcus Ware
Journal: Neuro-Oncology (2015)

INTRODUCTION: Spindle cell oncocytoma of the pituitary gland (SCO) describes a rare and relatively recently described non-endocrine neoplasm of the adenohypophysis that occurs in adults. These lesions tend to follow a clinically benign course and are designated as grade I by the World Health Organization (WHO) 2007 classification of tumors of the central nervous system. Diagnosis is often difficult, as clinically these masses can present very similarly to nonfunctional pituitary macroadenomas and are radiologically indistinguishable from adenomas and lymphocytic hypophysitis. To the best of our knowledge, there are 22 prior reported cases of SCO. CASE: A 59-year-old man presented with progressive headache for 3-weeks duration. On work up he was diagnosed with nonfunctional pituitary macroadenoma, and underwent complete transsphenoidal resection of the tumor. Histopathology ultimately revealed SCO. He has been stable without evidence of recurrence for 4 years. CONCLUSION: Spindle cell oncocytomas present similarly to nonfunctional adenomas and diagnosis is often difficult without surgical pathology. Despite this, SCO carry an increased risk of recurrence, and meticulous immunohistochemistry is warranted to prevent misdiagnosis after surgery. SCO should be considered in the differential diagnosis of sellar-region lesions.
PI3-kinase mutation linked to insulin and growth factor resistance in vivo
Authors: Jonathon N. Winnay, Marie H. Solheim, Ercument Dirice, Masaji Sakaguchi, Hye-Lim Noh, Hee Joon Kang, Hirokazu Takahashi, Kishan K. Chudasama, Jason K. Kim, Anders Molven, C. Ronald Kahn, Pål R. Njølstad
Journal: Journal of Clinical Investigation (2016)

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is central to the action of insulin and many growth factors. Heterozygous mutations in the gene encoding the p85α regulatory subunit of PI3K (PIK3R1) have been identified in patients with SHORT syndrome — a disorder characterized by short stature, partial lipodystrophy, and insulin resistance. Here, we evaluated whether SHORT syndrome–associated PIK3R1 mutations account for the pathophysiology that underlies the abnormalities by generating knockin mice that are heterozygous for the Pik3r1Arg649Trp mutation, which is homologous to the mutation found in the majority of affected individuals. Similar to the patients, mutant mice exhibited a reduction in body weight and length, partial lipodystrophy, and systemic insulin resistance. These derangements were associated with a reduced capacity of insulin and other growth factors to activate PI3K in liver, muscle, and fat; marked insulin resistance in liver and fat of mutation-harboring animals; and insulin resistance in vitro in cells derived from these mice. In addition, mutant mice displayed defective insulin secretion and GLP-1 action on islets in vivo and in vitro. These data demonstrate the ability of this heterozygous mutation to alter PI3K activity in vivo and the central role of PI3K in insulin/growth factor action, adipocyte function, and glucose metabolism.
Retention of a bile acid analogue in the enterohepatic circulation (EHC) in primary biliary cirrhosis (PBC): Comparison with normal controls and effect of bile acid treatment
Authors: M DETAVONATTI
Journal: Hepatology (1995)

To evaluate the prevalence and predictors of long-term impairment, epilepsy, mortality, and recurrences after the first stroke in a cohort of Chilean children.A prospective study involving 98 children who suffered a first stroke and underwent follow-up for at least 3 years in a single center. Functional outcome was measured using the modified Rankin Scale for children. We utilized multivariate logistic regression models to estimate the odds ratios (ORs) for outcomes while adjusting for age, sex, and underlying conditions (significance <.05).Stroke recurrences were present in 18 children and were strongly associated with arteriopathies (OR 8.11; CI 1.5-43). Of 26 children who died during the follow-up period, a significant proportion had a cardiopathy (OR 6.57; CI 1.3-32) or a chronic head and neck disease (OR 41.3; CI 3.5-490). Among 72 survivors (median age 1.49 years; 38 girls; mean follow-up time 4.85 years), 28 presented marked impairment; these children were younger (P = .019) and had more commonly arteriopathies (OR 9.33; CI 1.7-51) and epilepsy (OR 10.5; CI 3.1-36) as compared to survivors without disabilities. Cumulative epilepsy prevalence was 55.6%; children with epilepsy were younger (P = .037) and had more commonly acute symptomatic seizures (OR 12.16; CI 2.93-50.4) as compared to survivors without epilepsy.The prevalence of long-term adverse outcomes after childhood stroke is high and does not differ from other geographical and racial groups. Younger age, acute seizures, and arteriopathies but not sex and other underlying conditions predict adverse outcome following childhood stroke.
CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation
Authors: Yuan Liu, Elianna B. Amin, Marty W. Mayo, Neel P. Chudgar, Peter R. Bucciarelli, Kyuichi Kadota, Prasad S. Adusumilli, David R. Jones
Journal: Cancer Research (2016)

Breast cancer metastasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer (NSCLC) and other solid tumors, and its loss correlates with increased metastases. We show that BRMS1 is posttranslationally regulated by TNF-induced casein kinase 2 catalytic subunit (CK2α') phosphorylation of nuclear BRMS1 on serine 30 (S30), resulting in 14-3-3ε-mediated nuclear exportation, increased BRMS1 cytosolic expression, and ubiquitin-proteasome-induced BRMS1 degradation. Using our in vivo orthotopic mouse model of lung cancer metastases, we found that mutation of S30 in BRMS1 or the use of the CK2-specific small-molecule inhibitor CX4945 abrogates CK2α'-induced cell migration and invasion and decreases NSCLC metastasis by 60-fold. Analysis of 160 human NSCLC specimens confirmed that tumor CK2α' and cytoplasmic BRMS1 expression levels are associated with increased tumor recurrence, metastatic foci, and reduced disease-free survival. Collectively, we identify a therapeutically exploitable posttranslational mechanism by which CK2α-mediated degradation of BRMS1 promotes metastases in lung cancer. Cancer Res; 76(9); 2675-86. ©2016 AACR.
Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial
Authors: S. A. Wells, J. E. Gosnell, R. F. Gagel, J. F. Moley, D. G. Pfister, J. A. Sosa, M. Skinner, A. Krebs, J. Hou, M. Schlumberger
Journal: Journal of Clinical Oncology (2007)

6018 Background: Medullary thyroid cancer (MTC) is the most common cause of death in patients with hereditary syndromes caused by activating mutations in the RET protooncogene. RET activation is the initial oncogenic event, with the activity of other receptor tyrosine kinases, including VEGFR and EGFR, likely to contribute to tumor growth and metastasis. Vandetanib (ZD6474) is a once- daily oral agent that selectively targets RET, VEGFR and EGFR tyrosine kinases. Methods: Eligible patients had unresectable, measurable, locally advanced or metastatic hereditary MTC and a RET germline mutation. Patients received vandetanib 300 mg/day until disease progression or any other withdrawal criteria. The primary objective was to assess the objective tumor response (RECIST every 3 months). Secondary assessments included disease control rate, biochemical response (determined by decrements in plasma levels of calcitonin, a tumor marker for MTC) and safety and tolerability. Results: Thirty patients (21 female; median age 50 years) received initial treatment with vandetanib 300 mg. At data cut-off (20 Nov 2006), the median duration of treatment was 172 days. Based on site investigator assessments, 20% (6/30) of patients experienced a partial response (duration of response 59–260 days) and another 30% (9/30) of patients experienced stable disease =24 weeks, yielding a disease control rate of 50% (15/30). Centralized independent confirmation of response is planned. In 19 patients, plasma calcitonin levels showed a =50% decrease from baseline that was maintained for at least 6 weeks. Adverse events (AEs) occurring in &gt;50% of patients were rash (73%), diarrhea (67%), fatigue (57%) and nausea (53%). Most AEs were grade 1 or 2; grade 3 AEs included asymptomatic QTc prolongation (n=5), rash and diarrhea (both n=3), all of which were manageable. Conclusions: Vandetanib has demonstrated clinical activity in this phase II study in metastatic hereditary MTC, and the safety profile is generally consistent with previous vandetanib monotherapy studies. Accrual is now complete (30 patients), and an updated analysis will be performed in April 2007. An international, randomized, placebo-controlled phase II trial of vandetanib in MTC is now recruiting patients. # No significant financial relationships to disclose.
Clinicopathological analysis between exon 19 deletion and L858R in EGFR-mutant completely resected lung adenocarcinoma
Authors: Reiko Matsuzawa, Kiyotaka Yoh, Genichiro Ishii, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Seiji Niho, Hironobu Ohmatsu, Masahiro Tsuboi, Koichi Goto
Journal: Annals of Oncology (2015)
Effect of ICRF 159 on the Mammalian Cell Cycle: Significance for Its Use in Cancer Chemotherapy
Authors: K. Hellmann, E. O. Field
Journal: JNCI Journal of the National Cancer Institute (1970)

A quantitative cell culture technique was applied to the study of the mode of action of the cytostatic agent ICRF 159. The drug is not a general cytotoxic agent, but kills cells only during a brief period of the generation cycle. With the cell strain HEp/2, concentrations above 1.5 μg/ml were required for the lethal effect. The half-time of inactivation of the drug at 37° C in culture medium of pH 6.8–7.0 was of the order of 12 hours. These results agree with both clinical and experimental findings. Their implications for the therapeutic use of the drug are discussed.
Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study
Authors: V. Alberola, O. Gallego, G. López-Vivanco, C. Mesía, J. Oramas, J. M. Trigo, J. A. Virizuela, C. Camps, P. Regueiro, B. Massutí
Journal: Journal of Clinical Oncology (2007)

18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1 st , 2 nd and 3 rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p&lt;0.001) and cough was 24.7% vs 8.8 % (p&lt;0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p&lt;0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.